Overview

• In the 26-week, double-blind ADJUST-T1D trial of 72 adults using automated insulin delivery systems, 36% of those receiving semaglutide met composite targets of blood sugar control and weight loss compared with none on placebo.
• Semaglutide recipients achieved a 0.3% greater reduction in HbA1c from baseline than placebo (95% CI, –0.6 to –0.05).
• Patients on semaglutide spent 8.8% more time within the 70–180 mg/dL glucose range versus placebo (95% CI, 3.9–13.7).
• Treatment with semaglutide led to an average weight loss of 8.8 kg more than placebo (95% CI, –10.6 to –7).
• Gastrointestinal events affected 53% of semaglutide users versus 25% on placebo, and hypoglycemia rates remained low in both groups.